Mechanisms of Treatment Effects Using Cultured, Allogeneic Mesenchymal Stromal Stem Cells (MSCs) in Knee Osteoarthritis
Key facts
- Who runs it
- University Medical Centre Ljubljana
- Where
- Slovenia1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 30 people enrolled
- Started
- 1 Nov 2022
- Ended
- 1 Dec 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Knee aspiration + UCB-MSCs
- Knee aspiration
- Record updated
- 9 December 2024
Who can take part
- Age
- 50 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Patients with end-stage (Kellgren-Lawrence) knee osteoarthritis scheduled for knee arthroplasty
- Osteoarthritis of primary or post-traumatic etiology
Who cannot take part
- Anticoagulant therapy
- Rheumatic diseases
- Uncontrolled metabolic disorders
- Heart failure
- Renal failure
- Other conditions that may affect immune response or pose additional risk during cell application
- Secondary arthritis of other etiology
- Crystalopathies
- Coagulopathy
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to pharmacologically evaluate the effects of culturued allogeneic umbilical cord blood-derived mesenchymal stromal stem cell (UCB-MSCs) in the treatment of end-stage knee osteoarthritis (Kellgren-Lawrence grade 4) with the analysis of soluble biomarkers and expression of key genes, as well as the evaluation of clinical outcomes with patient-reported outcome measures (PROMs) and recording of potential complications.
Read full original descriptionShow less
Patients will be randomized in the intervention and control groups. In both groups, the knee aspiration will be performed 4-6 weeks prior to the knee arthroplasty to analyse baseline synovial fluid characteristics. The intervention group will receive the injection of UCB-MSCs. All patients will complete PROMs questionnaires and maintain a pain diary on visual analogue scale (VAS) at home until the surgery. On the day of admission to hospital for knee arthroplasty, the same questionnaires will be administered again. During the operative procedures, the samples of synovial fluid, synovial membrane and resected cartilage will be obtained and analysed afterwards.
It is anticipated that the study results will contribute to elucidate the mechanisms of action of MSCs in the treatment of knee osteoarthritis.
The 2 groups in the trial
- Intervention groupTreatment being tested
Knee aspiration and the application of UCB-MSCs
Treatment: Knee aspiration + UCB-MSCs
- Control groupExisting treatment, for comparison
Only knee aspiration, without the application of UCB-MSCs
Treatment: Knee aspiration
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Publications
- Synovial Biomarker Modulation and Clinical Response to Umbilical Cord-Derived MSC Treatment in Knee Osteoarthritis: A Case Series Study.Cartilage, 2026
- Mechanisms of treatment effects using allogeneic, umbilical cord-derived mesenchymal stromal stem cells (MSCs) in knee osteoarthritis: a pharmacological clinical study protocol.Trials, 2024
- Record updated
- 9 December 2024